CSPC Pharmaceutical Group

Diversified pharma

1093 · HKEX · China

Public Market Listing

1093HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for CSPC Pharmaceutical Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(11 total)
11Total Assets
0Approved
8Phase 3 / Filed
3Phase 1–2 / Early
11Diseases
Quick filter:
Showing 11 of 11 assets
Target & Modality
Phase 3
Serotonin/norepinephrine transporterSmall molecule
Major Depressive Disorder
Phase 3
HER2 (biparatopic — extracellular domains II and IV)Antibody–drug conjugate
Breast CancerColorectal Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Efmedaglutide alfa(Shanmeining)
Phase 3
GLP-1 receptorProtein / enzyme therapeutic
ObesityType 2 Diabetes
Phase 3
Angiotensin II type 1 receptor / L-type calcium channel (dual)Small molecule
Hypertension
Prusogliptin(Shanzeping)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 3
FLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Small molecule
Acute Myeloid Leukemia
Phase 3
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 3
JAK/SYKSmall molecule
Psoriasis
Phase 2
LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 2
ANGPTL3RNA / oligonucleotide
Atherosclerotic Cardiovascular DiseaseCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Preclinical / Unstaged
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Anbenitamab repodatecanPhase 3Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers
Est. primary completion 2026-12-30 · NCT06751485 · CT.gov ↗
What to watch
2027 (6)
April 2027 (2)
SYHX1901Phase 3Moderate to Severe Plaque Psoriasis
Est. primary completion 2027-04-28 · NCT06943950 · CT.gov ↗
What to watch
SYH2070Phase 2Mixed Hyperlipidemia
Est. primary completion 2027-04-30 · NCT07695597 · CT.gov ↗
What to watch
May 2027 (1)
SYHX1901Phase 2Severe Alopecia Areata
Est. primary completion 2027-05-31 · NCT06562894 · CT.gov ↗
What to watch
September 2027 (1)
SYH2070Phase 2Diagnosed With HoFH
Est. primary completion 2027-09-16 · NCT07591298 · CT.gov ↗
What to watch
December 2027 (2)
SYH2053Phase 3Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Est. primary completion 2027-12-31 · NCT07421284 · CT.gov ↗
What to watch
SYH2053Phase 3Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Est. primary completion 2027-12-31 · NCT07421297 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
SYH2053Phase 3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2028-02-28 · NCT07465263 · CT.gov ↗
What to watch
March 2028 (1)
SYH2068Phase 2Adult Participants With Elevated Lipoprotein(a)
Est. primary completion 2028-03-30 · NCT07640217 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026Topline resultTG103TG103 plus metformin Phase 3 vs dulaglutide (NCT06235086) met its primary endpoint
CSPC Pharmaceutical Group Limited · Source ↗
27 July 2026Topline resultAmmoxetinePhase III HA1406-007 of ammoxetine met its primary endpoint
CN · CSPC Pharmaceutical Group · Source ↗
27 July 2026Filing acceptedSirolimus for Injection (Albumin-Bound) (HB1901)NMPA accepts the HB1901 new drug application, with Priority Review
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
16 June 2026Filing acceptedSYH9056 (valsartan/levamlodipine maleate tablets)NMPA accepts CSPC's marketing authorisation application for SYH9056
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
16 June 2026Topline resultSYH9056 (valsartan/levamlodipine maleate tablets)SYH9056 Phase III: efficacy superior to either monotherapy
CSPC Pharmaceutical Group · Source ↗
June 2026Filing acceptedTG103NMPA accepts the second marketing application for efmedaglutide alfa (TG103, Shanmeining) in type 2 diabetes
China, NMPA · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Source ↗
20 April 2026Topline resultSirolimus for Injection (Albumin-Bound) (HB1901)Pivotal Phase Ib/III HB1901-004 study in advanced malignant PEComa met its primary endpoint
CSPC Pharmaceutical Group · Source ↗
October 2025Filing acceptedTG103NMPA accepts the BLA for efmedaglutide alfa (TG103) in overweight or obesity
China, NMPA · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.6B$809M$1.4B—report ↗